Exemplos de uso de Lifetime prevalence em Inglês e suas traduções para o Português
{-}
-
Colloquial
-
Official
-
Medicine
-
Financial
-
Ecclesiastic
-
Ecclesiastic
-
Computer
-
Official/political
Lifetime prevalence: about 14 million 4.1¢% of European adults.
In the United States and Canada the lifetime prevalence of at least one medical disease varies from 7.2% to 64.3.
Lifetime prevalence of NPD is estimated at 1% in the general population and 2% to 16% in clinical populations.
Of the three standard time frames used for reporting survey data, lifetime prevalence is the broadest.
The lifetime prevalence was much higher than that in the last 12 months.
Any use during a person's life(lifetime prevalence), often called‘lifetime experience';
Lifetime prevalence estimates ranged from 15% to 71% for ecstasy use and from 17% to 68% for amphetamines.
Schematic representation of increasing lifetime prevalence of illegal drug use with age during adolescence.
The lifetime prevalence estimates of any DSM-IV/CIDI disorder ranges interquartile range across countries from 18.1%-36.1.
As a point of contrast, Greece, Cyprus, Romania, Sweden, Turkey andNorway all report lifetime prevalence estimates lower than 10.
Todaro et al reported the lifetime prevalence of anxiety disorders to be 45.3% in patients with CAD.
OCD is not a rare disorder, with an estimated point prevalence of approximately 1% and lifetime prevalence of 2.
The objectives of this study were to identify the lifetime prevalence and presumed mechanisms of TLC in an urban Russian population.
In 2005, lifetime prevalence rates for any drug use were 21%, 38%, and 50% in grades 8, 10, and 12, respectively.
ESPAD study among 15- and 16-year-old schoolchildren- Lifetime prevalence ofany drug use, excluding alcohol(once in their life) in.
In this group, lifetime prevalence can be a useful measure, since the age gradient reflects the rate at which drug experience increases during adolescence see Figure 2.
In Ireland and the United Kingdom,which have long histories of cannabis use, lifetime prevalence is high but has remained stable during the last decade.
Statistical Table 1: Lifetime prevalence(LTP) of drug use inrecent nationwide surveys among the general population in the EU countries and Norway.
Cannabis remains the most commonly used drug in the EU,with many countries reporting lifetime prevalence rates inexcess of 20% of the general population.
Our findings demonstrate that the lifetime prevalence was greater among construction workers, with the exception of inhalant drugs, which presented similar values.
Despite this wide overall range, 12 European countries out of the 26 that provided information reported lifetime prevalence rates in the range 10-25% 32.
On the other hand,the literature shows a lifetime prevalence of 16% in the general population, namely, 8% among men and 25% among women.
In the third group of Member States(Finland andSweden in the north and Greece, Cyprus and Malta in the south) plus Norway, estimates of lifetime prevalence among school students have remained at relatively low levels around 10% and below.
See Statistical Table 1: Lifetime prevalence(LTP) of drug use in recent nationwide surveys among the general population in the EU countries and Norway.
Half of the countries report lifetime prevalence rates of 2.5% or lower, with the highest prevalence rates being reported by the United Kingdom(7.2%), the Czech Republic(7.1%), Spain(4.4%) and the Netherlands 4.3.
Of the three standard time frames used for reporting survey data, lifetime prevalence(use of a drug at any point in one's life) is the broadest.
Among young adults(15-34 years), lifetime prevalence of amphetamines use varies considerably between countries, from 0.1% to 15.3%, with a weighted European average of about 5.
The recent National Comorbidity Survey- Replication NCS-R obtained data from 9282 English-speaking adults across the continental USA,finding lifetime prevalence estimates of 1% for bipolar I and 1.1% for bipolar II, with a further 2.4% having subthreshold BD.
In thecase of the United Kingdom,decreased lifetime prevalence ofboth cannabis and ecstasy was accompanied by a decrease in perceived availability(163)(164) and an increase indisapproval 165.